HC Wainwright restated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Wednesday morning. The brokerage currently has a $30.00 target price on the stock.
“We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta- refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and estimated YE18 fully diluted net cash of $2.09/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x.”,” HC Wainwright’s analyst commented.
KPTI has been the topic of a number of other reports. BidaskClub downgraded Karyopharm Therapeutics from a buy rating to a hold rating in a report on Saturday, September 29th. ValuEngine downgraded Karyopharm Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, October 11th. Zacks Investment Research raised Karyopharm Therapeutics from a hold rating to a buy rating and set a $21.00 price target on the stock in a report on Wednesday, July 25th. Canaccord Genuity reaffirmed a buy rating and set a $27.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. Finally, Robert W. Baird reaffirmed a buy rating and set a $25.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Karyopharm Therapeutics presently has a consensus rating of Buy and an average price target of $22.90.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.09. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.21 million. As a group, equities research analysts expect that Karyopharm Therapeutics will post -3.18 earnings per share for the current year.
In other Karyopharm Therapeutics news, insider Sharon Shacham sold 12,500 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $19.31, for a total value of $241,375.00. Following the transaction, the insider now owns 726,010 shares of the company’s stock, valued at $14,019,253.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ltd Chione sold 11,468 shares of the stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $21.05, for a total value of $241,401.40. The disclosure for this sale can be found here. In the last three months, insiders sold 735,788 shares of company stock worth $14,720,105. 13.26% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of KPTI. BlackRock Inc. lifted its holdings in Karyopharm Therapeutics by 47.0% in the second quarter. BlackRock Inc. now owns 4,055,634 shares of the company’s stock valued at $68,905,000 after acquiring an additional 1,297,571 shares during the period. Candriam Luxembourg S.C.A. raised its stake in shares of Karyopharm Therapeutics by 120.6% in the third quarter. Candriam Luxembourg S.C.A. now owns 1,085,500 shares of the company’s stock worth $18,486,000 after buying an additional 593,500 shares during the period. Emerald Advisers Inc. PA bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $9,537,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $8,116,000. Finally, Macquarie Group Ltd. bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $5,787,000. 71.83% of the stock is currently owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Article: Return on Equity (ROE)
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.